Biohaven Pharmaceutical Holding Company Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Biohaven Pharmaceutical Holding Company Ltd.
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.
Panelists at a recent Duke-Margolis meeting cite growing use of native ads and patient influencers, as well as the limited attention given to presentation of risk information, in calling for a re-examination of how pharmaceutical promotion on digital platforms is regulated.
Chief development officer William Pao will depart the company in a sudden transition after being recruited from Roche. Pfizer insiders Chris Boshoff and Mikael Dolsten will fill the roles.
Almost 80% of novel agent submissions from the biggest companies were approved in recent years, compared with a 60% approval rate for the rest of the industry, according to a recent analysis of FDA approval decisions since 2021.
- Controlled Release
- Drug Delivery
- Large Molecule
- Other Names / Subsidiaries
- Biohaven Pharmaceuticals, Inc.
- Biohaven Therapeutics Ltd.
- Kleo Pharmaceuticals Inc.
- Portage Biotech Inc.
- Portage Glasgow Limited (PGL)
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.